Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
Notified -
Globe Newswire21-11-2024, 04:05
Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26